{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:11:58Z","timestamp":1775067118740,"version":"3.50.1"},"reference-count":50,"publisher":"Informa UK Limited","issue":"8","funder":[{"name":"This study was not funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2022,8,3]]},"DOI":"10.1080\/14740338.2022.2045945","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T19:03:17Z","timestamp":1645642997000},"page":"1121-1126","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-3922","authenticated-orcid":false,"given":"Richard","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vrishali L.","family":"Lopes","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Rhode Island College of Pharmacy, Kingston, Rhode Island USA"},{"name":"Infectious Disease Outcomes Research Program, Veterans Affairs Medical Center, Providence, Rhode Island, USA"},{"name":"Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4180-027X","authenticated-orcid":false,"given":"Aisling R.","family":"Caffrey","sequence":"additional","affiliation":[{"name":"Infectious Disease Outcomes Research Program, Veterans Affairs Medical Center, Providence, Rhode Island, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,3,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8654-z"},{"issue":"7","key":"cit0002","first-page":"506","volume":"64","author":"Czarnobilska E","year":"2007","journal-title":"Przegl Lek"},{"key":"cit0003","volume-title":"StatPearls","author":"Oakley AM","year":"2022"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14591"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2012.27.2.203"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.03.023"},{"key":"cit0008","unstructured":"Stevens-Johnson syndrome\/toxic epidermal necrolysis - genetics home reference - NIH. (2020, May 12). cited 2020 May 18 from https:\/\/ghr.nlm.nih.gov\/condition\/stevens-johnson-syndrome-toxic-epidermal-necrolysis#definition"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15360"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2295"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1086\/429323"},{"key":"cit0012","unstructured":"Colistimethate. In: Lexi-drugs online [database on the Internet]. Hudson (OH): Lexicomp, Inc. 2016 [updated 18 May 2020; cited 19 May 2020]. Available from: http:\/\/online.lexi.com. Subscription required to view."},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00873-8"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1186\/2110-5820-1-14"},{"key":"cit0015","unstructured":"Center for Drug Evaluation and Research. (2018, June 04). Questions and answers on FDA\u2019s Adverse Event Reporting System (FAERS). Retrieved 2020 Jun 11, from https:\/\/www.fda.gov\/drugs\/surveillance\/questions-and-answers-fdas-adverse-event-reporting-system-faers"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.11.025"},{"key":"cit0017","unstructured":"Colistin. (2020, March 15). cited 2020 Mar 16, from https:\/\/www.drugbank.ca\/drugs\/DB00803"},{"key":"cit0018","unstructured":"Dean AG, Sullivan KM, Soe MM OpenEpi: open source epidemiologic statistics for public health, version. www.OpenEpi.com, updated 2013\/april\/06, cited 2020 march 19."},{"key":"cit0019","volume-title":"DailyMed","author":"National library of medicine (U.S.)","year":"2005"},{"key":"cit0020","volume-title":"Colistin","year":"2017"},{"key":"cit0021","volume-title":"Coly-Mycin M Parenteral","year":"2006"},{"key":"cit0022","unstructured":"IBM micromedex\u00ae DRUGDEX\u00ae (electronic version). IBM Watson health, Greenwood Village, Colorado USA. Available at: https:\/\/www.micromedexsolutions.com\/ (cited 2020 may 28)."},{"key":"cit0023","volume-title":"Ciprofloxacin","year":"2016"},{"key":"cit0024","volume-title":"Amphotericin B","year":"2009"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205577"},{"key":"cit0026","first-page":"1","volume-title":"Side-effects of anti-inflammatory drugs, advances in inflammation research","author":"Weber J","year":"1984"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0150-2"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0115-x"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.8.743.36068"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S137144"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4672"},{"key":"cit0032","unstructured":"Drug safety communication. Available at http:\/\/wayback.archive\u2010it.org\/7993\/20171115033743\/https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm250913.htm. cited 2018 Aug 7."},{"key":"cit0033","unstructured":"Mercaptopurine (purinethol) labeling approved may 27, 2011 (PDF\u201060KB). Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/009053s032lbl.pdf. cited 2018 Aug 7."},{"issue":"3","key":"cit0034","first-page":"160","volume":"11","author":"Montgomery M","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"cit0035","unstructured":"Conjugated estrogens (premarin) labelling approved October 28, 2011 (PDF\u2010310KB). Available at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/004782s162s164s167lb.pdf. cited 2018 Aug 7"},{"key":"cit0036","unstructured":"Orphan drug act of 1983. Pub L. No. 97\u2013414, 96 Stat. 2049."},{"key":"cit0037","unstructured":"FAQs about rare diseases. (2017, November 30). cited 2020 Jul 21, from https:\/\/rarediseases.info.nih.gov\/diseases\/pages\/31\/faqs-about-rare-diseases"},{"key":"cit0038","unstructured":"Rare diseases. (2020, June 24). cited 2020 Jul 21, from https:\/\/ec.europa.eu\/info\/research-and-innovation\/research-area\/health-research-and-innovation\/rare-diseases_en"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.11.023"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250049006"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670250043005"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4209"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0063-5"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1002\/pds.615"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2003.20130.x"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.8.743.36068"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1001"},{"key":"cit0048","unstructured":"U.S. Food & Drug Administration. Questions and answers on FDA\u2019s adverse event reporting system (FAERS). U.S. Department of Health and Human Services; 2018."},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S142226"},{"issue":"3","key":"cit0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/2045-7022-4-S3-P89","volume":"4","author":"Nakamura R","year":"2014","journal-title":"Clin Transl Allergy"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2022.2045945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:14:47Z","timestamp":1700266487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2022.2045945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,3]]}},"alternative-id":["10.1080\/14740338.2022.2045945"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2022.2045945","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-01-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}